NCT03180073

Brief Summary

Most of the conduction abnormalities with TAVR are usually detected during the procedure or during the following days of observation. Little is known about the prevalence and timing of any conduction abnormalities that exist before (other than standard ECG) or after through long term cardiac monitoring.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jun 2017

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 9, 2017

Completed
28 days until next milestone

Study Start

First participant enrolled

June 6, 2017

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 8, 2017

Completed
3.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 23, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 23, 2020

Completed
Last Updated

February 21, 2021

Status Verified

February 1, 2021

Enrollment Period

3.6 years

First QC Date

May 9, 2017

Last Update Submit

February 17, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Need for Pacemaker post TAVR

    the prevalence of brady arrhythmia (Sinus brady, Sinus Pauses, AV Block, Bundle Branch Block) among patients with severe aortic stenosis who undergo TAVR using an extended cardiac rhythm monitor (Zio Patch) and determine if the brady arrhythmias predict the need for a pacemaker.

    2 months prior to TAVR

Secondary Outcomes (3)

  • Prevalence of in hospital brady arrhythmia post TAVR

    72 hours post TAVR

  • Prevalence of brady arrhythmia after discharge from hospital post TAVR

    3 weeks post discharge

  • Prevalence of delayed brady arrhythmia post TAVR

    2 months post TAVR

Interventions

Ziopatch Pre dischargeDIAGNOSTIC_TEST

Ziopatch applied 2 weeks prior to procedure

Ziopatch at DischargeDIAGNOSTIC_TEST

Ziopatch applied at discharge from hospital to be worn for 2 weeks

Ziopatch at 2 monthsDIAGNOSTIC_TEST

Ziopatch applied 2 months from procedure to be worn for 2 weeks

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients to be scheduled for TAVR without preexisting Cardiac Implantable Electronic Device (CIED) can be screen and enrolled

You may qualify if:

  • Age \> 18 and \<90 years old
  • Able to provide informed consent
  • Willing to follow up at Cleveland Clinic (per TAVR protocol)

You may not qualify if:

  • Prior CIED (Pacemaker or defibrillator)
  • Unable to provide consent
  • Unable to follow up at Cleveland Clinic per TAVR protocol

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cleveland Clinic

Cleveland, Ohio, 44195, United States

Location

Related Publications (1)

  • Tarakji KG, Patel D, Krishnaswamy A, Hussein A, Saliba W, Wilkoff BL, Wolski K, Svensson L, Wazni OM, Kapadia SR. Bradyarrhythmias detected by extended rhythm recording in patients undergoing transcatheter aortic valve replacement (Brady-TAVR Study). Heart Rhythm. 2022 Mar;19(3):381-388. doi: 10.1016/j.hrthm.2021.11.020. Epub 2021 Nov 18.

MeSH Terms

Conditions

Bradycardia

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Khaldoun Tarakji, MD

    The Cleveland Clinic

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

May 9, 2017

First Posted

June 8, 2017

Study Start

June 6, 2017

Primary Completion

December 23, 2020

Study Completion

December 23, 2020

Last Updated

February 21, 2021

Record last verified: 2021-02

Data Sharing

IPD Sharing
Will not share

Locations